Calcium and sodium handling during volume expansion in essential hypertension

Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension

Although supplemental calcium typically lowers blood pressure in subjects with salt-sensitive, low-renin hypertension - presumably by down-regulating increased production of parathyroid hormone (PTH) and/or parathyroid hypertensive factor (PHF) - its impact on the blood pressure of unselected hypertensive or normotensive subjects, as assessed by meta-analyses, appears to be trivial at best. This suggests that calcium may actually raise blood pressure a bit in some patients with high-renin hypertension, a prediction that is borne out in rodent models of this disorder. There is limited clinical evidence that long-term calcium supplementation tends to raise plasma renin activity; this finding, if valid, could evidently rationalize the equivocal clinical impact of calcium on blood pressure. Salt restriction likewise boosts renin production, and this effect tends to most notable in subjects whose blood pressure fails to decline during low-salt diets. Two clinical groups have demonstrated that salt restriction has a larger and more consistently beneficial impact on the blood pressure of hypertensives when they concurrently are treated with ACE inhibitors - evidently because the physiological impact of the associated rise in renin is blunted. Analogous logic suggests that calcium supplementation may be more beneficial for hypertensives in the context of ACE inhibition or blockade of angiotensin II receptors; this supposition that can readily be tested clinically. The imminent availability of safe nutraceutical ACE inhibitors may make it more feasible for the general public to benefit from these therapeutic/preventive possibilities.

Marinobufagenin may mediate the adverse impact of salty diets on renal calcium retention by impairing the efficiency of renal tubular sodium–calcium exchange

For reasons yet to be clarified, salt loading and plasma volume expansion decrease renal calcium retention; consequently, high-salt diets are thought to increase risk for osteoporosis and renal stones. These measures also can evoke increased adrenal production of the natriuretic factor marinobufagenin (MBG), recently implicated in the genesis of essential hypertension. MBG achieves natriuresis via potent selective inhibition of the alpha-1-type sodium pump, expressed throughout the nephron. In as much as renal calcium retention is largely dependent on efficient activity of calcium-sodium exchangers situated in the basolateral membranes of tubular epithelium, it is evident that an increased intracellular sodium concentration consequent to sodium pump inhibition could blunt the activity of these exchangers. Thus, it is postulated that MBG mediates the impact of salt loading on renal calcium retention.

Plasma fatty acids response to central volume expansion in salt-sensitive hypertension

The purpose of the present study was to investigate the possible regulation of plasma fatty acids by an acute isotonic-isooncotic central volume expansion. We measured the levels of nonesterified fatty acids (NEFA) in plasma from 12 essential hypertensive patients subjected to water immersion (WI). Central hypervolemia by WI over 2 hours caused the levels of most NEFA to increase, concomitantly with a marked natriuretic and kaliuretic response. With respect to baseline values, serum insulin levels did not change during WI, while there was a profound suppression of plasma renin activity (PRA) and plasma aldosterone. In addition, when individual NEFA percent increase was expressed as a function of salt-sensitivity index (calculated as the change in mean arterial pressure [MAP] divided by the change in urinary sodium excretion rate), a greater percent increase in stearic acid (r =.72, P <.009), palmitic acid (r =.83, P <.001), and palmitoleic acid (r =.58, P <.048) was found during WI in those hypertensive subjects showing higher salt-sensitivity index. Thus, by demonstrating that an acute isotonic-isooncotic volume expansion may induce a significant increase of most NEFA plasma levels, we suggest that volume expansion per se could be included among the well-recognized risk factors for cardiovascular morbid events.

A prospective study of hypertension and the incidence of kidney stones in men

OBJECTIVE

To examine whether hypertension predicts the incidence of kidney stone disease.

DESIGN

Prospective cohort study (the Olivetti Prospective Heart Study).

SETTING

The Olivetti factory in Southern Italy.

SUBJECTS

Five hundred and three male workers, aged 21 - 68 years, with no evidence of kidney stone disease at baseline. Follow-up 8 years.

MAIN OUTCOME MEASURES

Anthropometry, blood pressure, biochemistry and history of kidney stone disease were evaluated at the baseline examination in 1987. Occurrence of kidney stone disease was evaluated again in 1994-1995. Hypertension was defined as systolic blood pressure > or = 160 or diastolic blood pressure, > or = 95 mmHg or both, or being on drug therapy for hypertension. Occurrence of kidney stone disease was defined as radiological or echographic evidence of calculi or documented passage of one or more stones.

RESULTS

At baseline, 114/503 men (22.7%) had hypertension and 32 were on drug treatment. After 8 years, 52 (10.3%) incident cases of kidney stone disease were detected. The majority (n = 45) had a documented passage of one or more stones. The incidence of kidney stone disease was higher in hypertensive than in normotensive men (19/114 (16.7%) versus 33/389 (8.5%); P = 0.011). Hypertensive men had a greater risk of developing kidney stones than normotensive ones (RR 1.96; 95% confidence interval 1.16-3.32). The risk was unaffected by the exclusion of treated hypertensives (2.01; 1.13-3.59) and after adjustment for age (1.89; 1.12-3.18), body weight (1.78; 1.05-3.00) or height (2.00; 1.19-3.38).

CONCLUSIONS

Hypertension in middle-aged men is a significant predictor of kidney stone disease rather than a consequence of renal damage caused by the kidney stones.